ViiV Healthcare offers evidence that its two-drug regimen is as good as three in HIV

6 October 2020
viiv-big

Three-year results from the Phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress have been presented by ViiV Healthcare, the HIV specialist company majority-owned by GlaxoSmithKline (LSE: GSK).

Findings showed that the two-drug regimen (2DR) of dolutegravir plus lamivudine, which is marketed as Dovato, continued to offer non-inferior efficacy, a high genetic barrier to resistance and a comparable safety profile versus a three-drug regimen of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-naïve adults with HIV-1.

Pedro Cahn, scientific director, Fundación Huésped, professor of Infectious Diseases, Buenos Aires University Medical School, and principal investigator for the GEMINI study program, said: “These long-term data confirm that dolutegravir-based two-drug regimens have a rightful place in the HIV treatment compendium. Dolutegravir plus lamivudine continues to demonstrate long-term non-inferior efficacy compared to dolutegravir plus TDF/FTC with benefits beyond viral suppression.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical